Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Hunt

Sports Medicine Cedar Knolls, NJ Medical Doctor

NPI 1457440711 CMS profile 111674

197 Ridgedale Ave, Cedar Knolls, NJ 07927

Open in the dashboard

General payments

$75,641

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Hunt of Cedar Knolls, NJ is reported in the CMS Open Payments database as having received $75,641 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,386 14
2024 General $18,970 15
2023 General $14,674 11
2022 General $58 4
2021 General $8,890 6
2020 General $5,389 6
2019 General $8,273 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Hunt
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Stephen Hunt were reported at $19,386. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Stephen Hunt Sports Medicine median Middle half National median
2019 $8,273 $1,176 $199–$4,249 $163
2020 $5,389 $708 $96–$2,890 $114
2021 $8,890 $1,213 $152–$3,994 $132
2022 $58 $1,230 $159–$3,998 $149
2023 $14,674 $584 $146–$2,836 $160
2024 $18,970 $628 $163–$3,168 $164
2025 $19,386 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $64,412 43 payments
  2. Smith+Nephew, Inc. $10,920 22 payments
  3. Miach Orthopaedics, Inc. $140 1 payment
  4. Kowa Pharmaceuticals America, Inc. $42 3 payments
  5. Orthofix Medical, Inc. $31 1 payment
  6. SeaPearl Inc $26 1 payment
  7. DePuy Synthes Sales Inc. $22 1 payment
  8. FUJIFILM Medical Systems USA, Inc. $20 1 payment
  9. Pacira Pharmaceuticals Incorporated $16 1 payment
  10. Ferring Pharmaceuticals Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $60,550 16 payments
  2. Travel and Lodging $8,437 17 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,275 1 payment
  4. Food and Beverage $2,379 41 payments
Products named General payments · program years 2019–2025
  1. NA $15,353 3 payments
  2. FLEXIBLE GUIDE PIN (STRYKER ACL VERSITOMIC) $13,300 2 payments
  3. TRIATHLON $10,400 1 payment
  4. AEQUALIS $10,400 1 payment
  5. ICONIX $6,644 10 payments
  6. Coblation Wands $4,959 9 payments
  7. HIP ARTHROSCOPY ACCESS & INSTRUMENTATION SET $4,400 2 payments
  8. SALVATION $3,748 9 payments
  9. HIPMAP $2,800 2 payments
  10. NANOTACK FLEX $2,613 2 payments
  11. Other $5,210 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Orthopedic Surgery: 203

Drug cost

$450

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 18 $346
Meloxicam Generic 19 $67
Amoxicillin Generic 14 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$66,986

Of which drugs: $543

Medicare patients

323

Average age 73

Services billed

1,033

197 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 66%
High blood pressure 63%
Ischemic heart disease 25%
Diabetes 20%
Osteoporosis 20%
Cancer 15%
Atrial fibrillation 13%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 46 208 $153

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record